A Phase IIb, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis
Latest Information Update: 20 Jun 2024
At a glance
- Drugs Amlitelimab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms STREAM-AD
- Sponsors Kymab
- 12 Mar 2024 Results of 24-week secondary outcomes of AD extent and severity , presented at the American Academy of Dermatology annual Meeting 2024
- 12 Mar 2024 Results of patient-reported outcome (PRO), presented at the American Academy of Dermatology annual Meeting 2024
- 11 Mar 2024 Results presented in the Sanofi Media Release.